Thomas Hoeg-Jensen, scientific director, Novo Nordisk A/S
THJ has 26 years of experience in design, preparation and evaluation of diabetes-related peptide and protein drug candidates, and Thomas is co-inventor of insulin degludec (Tresiba) and the basal-bolus co-formulation with insulin aspart (Ryzodeg), both of which are marketed by Novo Nordisk. THJ’s current main research focus is glucose-sensitive insulin, of which the most advanced project recently reached early-stage clinical trials. THJ is adjunct professor at University of Copenhagen, and apart from drug discovery his research has included novel protein conjugation methods, glucose binding molecules and chemoinformatic systems for chemically modified proteins. When THJ is not in front of the computer, he plays tennis and saxophone.